Cephalon Board Rejects Valeant's $5.7B Merger Bid
Cephalon Inc. on Tuesday spurned Valeant Pharmaceuticals International Inc.'s $5.7 billion buyout bid, blasting the offer as inadequate and opportunistic, while Valeant vowed to turn to Cephalon shareholders to remove the...To view the full article, register now.
Already a subscriber? Click here to view full article